Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4838-4848

  Moyer, James D ^a,d   Barbacci, Elsa G ^a   Iwata, Kenneth K ^b   Arnold, Lee ^a   Boman, Bruce ^c   Cunningham, Ann ^a   DiOrio, Catherine ^a   Doty, Jonathan ^a   Morin, Michael J ^a   Moyer, Mikel P ^a   Neveu, Mark ^a   Pollack, Vincent A ^a   Pustilnik, Leslie R ^a   Reynolds, Margaret M ^b   Sloan, Don ^a   Theleman, April ^b   Miller, Penny ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Oncogene Science Inc   (United States)

^c Storz Cancer Institute   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CELL SURVIVAL; DIAGNOSIS; DNA CONTENT; DNA STRAND BREAKAGE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CELL CYCLE; CELL DIVISION; DNA FRAGMENTATION; DNA, NEOPLASM; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 0030774045     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Ullrich, A., and Schlessinger, J. Signal transduction hy receptors with tyrosine kinase activity. Cell, 61: 203-212, 1990.
2. Modjtahedi, H., and Dean, C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int. J. Oncol., 4: 277-296, 1994.
3. Gullick, W. J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull., 47: 87-98, 1991.
4. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19: 183-232, 1995.
5. Yamazaki, H., Fukui, Y., Ueyama, Y., Tamaoki, N., Kawamoto, T., Taniguchi, S., and Shibuya, M. Amplification of the structurally and functionally altered epidermal growth factor receptor (c-erbB) in human brain tumors. Mol. Cell. Biol., 8: 1816-1820, 1988.
6. Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez., G., Gunn, G., Zoltick, P. W., Biegel, J. A., Hayes, R. L., and Wong, A. J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55: 5536-5539, 1995.
7. Wickstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D. K., Pegram, C. N., Reist, C. J., Traweek, S. T., Wong, A. J., Zalulutsky, M. R., and Bigner, D. D. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res., 55: 3140-3148, 1995.
8. Baselga, J., and Mendelsohn, J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat., 29: 127-138, 1994.
9. Bridges, A. J. The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target? Curr. Med. Chem., 3: 167-194, 1996.
10. Davies, D. E., and Chamberlin, S. G. Targeting the epidermal growth factor for chemotherapy of carcinomas. Biochem. Pharmacol., 51: 1101-1110, 1996.
11. Chakrabarty, S., Rajagopal, S., and Huang, S. Expression of antisense epidermal growth factor receptor RNA down-modulates the malignant behavior of human colon cancer cells. Clin. Exp. Metastasis. 13: 191-195, 1995.
12. De Giovanni, C., Landuzzi, L., Frabetti, F., Nicoletti, G., Griffoni, C., Rossi, I., Mazzotti, M., Scotto, L., Nanni, P., and Lollini, P-L. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res., 56: 3898-3901, 1996.
13. Redemann, N., Holzmann, B., vonRuden, T., Wagner, E. F., Schlessinger, J., and Ullrich, A. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol. Cell. Biol., 72: 491-498, 1992.
14. Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J., Polikoff, J., and Sato, G. H. Biological effect in vitro of monoclonal antibodies to human EGF receptors. Mol. Biol. Med., 1: 511-529, 1983.
15. Modjtahedi, H., Styles, J., and Dean, C. The growth response of human tumor cell lines expressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding. Int. J. Oncol., 3: 237-243, 1993.
16. Gross, M. E., Zorbas, M. A., Danels, Y. J., Garcia, R., Gallick, G. E., Olive, M., Brattain, B. M., Boman, B. M., and Yeoman, L. C. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res., 51: 1452-1459, 1991.
17. Masui, H., Boman, B., Hyman, J., Castro, L., and Mendelsohn, J. Treatment with anti-EGF monoclonal antibody causes regression of DiFi human colorectal carcinoma xenografts. Proc. Am. Assoc. Cancer Res., 32: 394, 1991.
18. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
19. Mendelsohn, J. EGF receptor blockade as anticancer therapy. Proc. Am. Assoc. Cancer Res., 37: 647-648, 1996.
20. Yaish, P. A., Gazit P., Gilon, C., and Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (Washington DC), 242: 933-935, 1988.
21. Lyall, R. M., Zilverstein, A., Gazit, A., Gilon, C., Levitzki, A., and Schlessinger, J. Tyrphostins inhibit EGF receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem., 264: 14503-14509, 1989.
22. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
23. Buchdunger, E., Mett, H., Trinks, U., Regenass, U., Müller, M., Meyer, T., Beilstein, P., Wirz, B., Schneider, P., Traxler, P., and Lydon, N. B. 4,5-Bis-(4-fluoroanilino)-phtalimide: a selective inhibitor of the epidermal growth factor receptor signalling pathway with potent antitumor activity. Clin. Cancer Res., 1: 813-821, 1995.
24. Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C. Mourton, T., Herrup, K., Harris, R. C., Barnard, J. A., Yuspa, S. T., Coffey, R. J., and Magnuson, T. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (Washington DC), 269: 230-234, 1995.
25. Sibilia, M., and Wagner, E. F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science (Washington DC), 269: 234-237, 1995.
26. Luetteke, N. C., Phillips, H. K., Qui, T. H., Copeland, N. G., Earp, H. S., Jenkins, N. A., and Lee, D. C. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev., 8: 399-413, 1994.
27. Modjtahedi, H., Eccles, S., Sandle, J., Box, G., Titley, J., and Dean, C. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res., 54: 1695-1701, 1994.
28. Wu, X., Fan, Z., Masui, H., Rosen, N., and Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest., 95: 1897-1905, 1995.
29. Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H. L., Kajstura, J., Rubin, R., Zollick, P., and Baserga, R. The insulin-like growth factor I receptor protects tumor cells form apoptosis in vivo. Cancer Res., 55: 2463-2469, 1995.
30. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13: 3286-3295, 1994.
31. Arnold, L. D., and Schnur, R. C. Novel anti-proliferative quinazoline derivatives useful for treating tumours, inflammatory disorders etc. World Patent Application No. WO9630347.
32. Olive, M., Untawale, S., Coffey, R. J., Siciliano, M. J., Wildrick, D. M., Fritsche, H., Patahk, S., Cherry, L. M., Blick, M., Lointier, P., Roubein, L. D., Levin, B., and Boman, B. M. Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient. In Vitro Cell. Dev. Biol., 29A: 239-248, 1993.
33. Easty, D. M., Easty, G. C., Carter, R. L., Monaghan, P., and Butler, L. J. Ten human carcinoma lines derived from squamous carcinomas of the head and neck. Br. J. Cancer, 43: 772-785, 1981.
34. Reynolds, F. H., Van deVen, W. J. M., and Slephenson, J. R. Feline sarcoma virus P115-associated protein kinase phosphorylates tyrosine. J. Biol. Chem., 255: 11040-11047, 1980.
35. Schrang, B., Staal, G. E. J., Adriaansen-Slot, S. S., Salden, M., and Rijksen, G. Standardization of an enzyme-linked immunosorbant assay for the determination of protein tyrosine kinase activity. Anal. Biochem., 211: 233-239, 1993.
36. Gill, G. N., and Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol., 146: 82-92, 1987.
37. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 277: 680-685, 1970.
38. Taylor, I. W. A rapid single-step staining technique for DNA analysis by flow cytometry. J. Hislochem. Cytochem., 28: 1021-1024, 1980.
39. Li, X., Melamed, M., and Darzynkiewicz, Z. Detection of apoptosis and DNA replication by differential labeling of DNA strand breaks with fluorochromes of different color. Exp. Cell Res., 222: 23-37, 1996.
40. Sasaoka, T., Rose, D. W., Jhun, B. H., Saltiel, A. R., Draznin, B., and Olefsky, J. M. Evidence for a functional role of SHC proteins in mitogenic signalling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J. Biol. Chem., 269: 13689-13694, 1994.
41. Soler, C., Alvarez, C. V., Beguinot, L., and Carpenter, G. Potent SHC tyrosine phosphorylation by epidermal growth factor receptor at low receptor density or in the absence of receptor autophosphorylation sites. Oncogene, 9: 2207-2215, 1994.
42. Fujita-Yamagutchi, Y., and Kathuria, S. Characterization of receptor specific protein tyrosine kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-I receptor. Biochem. Biophys. Res. Commun., 157: 955-962, 1988.
43. r 55,000 substrate with the receptor. Proc. Natl. Acad. Sci. USA. 89: 8477-8481, 1992.
44. Untawale, S., Zorbas, M. A., Hodgson, C. P., Coffey, R. J., Gallick, G. E., North, S. M., Wildrick, D. M., Olive, M., Blick, M., Yeoman, L. C., and Boman, B. M. Transforming growth factor-α production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene. Cancer Res., 3: 1630-1636, 1993.
45. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
46. Darzynkiewicz, Z., Juan, G., Li, X., Gorczyca, W., Murakami, T., and Traganos, F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 27: 1-20, 1997.
47. Gavrieli Y., Sherman Y., and Ben-Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol., 119: 493-501, 1992.
48. Martin, S. J., Reutelingsperger, C. P. M., McGahon, A. J., Rader, J. A., van Schie, R. C. A. A., LaFace, D. M., and Green, D. R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med., 182: 1545-1556, 1996.
49. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y. L., and Davidson, N. E. Specific proteolytic cleavage of poly( ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
50. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirer, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 371: 346-347, 1994.
51. Pelici, G., Lanfrancone, L., Salcini, E. S., Romano, A., Mele, S., Borello, M. G., Segatto, O., DiFiore, P. P., and Pelicci, P. G. Constitutive phosphorylation of She proteins in human tumors. Oncogene, 10: 899-907, 1995.
52. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 12: 1397-1402, 1996.
53. Pierce, J. H., Ruggiero, M., Fleming, T. P., DiFiore, P. P., Greenberger, J. S., Varticovski, L., Schlessinger, J., Rovera, G., and Aaronson, S. A. Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science (Washington DC), 239: 628-631, 1988.
54. Nagane, M., Coufal, F., Lin, H., Bogler, O., Cavenee, W. K., and Su Huang, H-J. A common mutant growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res., 56: 5079-5086, 1996.
55. Rodeck, U., Jost, M., Dari, C., Shih, D-T., Lavker, R. M., Ewert, D. L., and Jensen, P. J. EGFR-dependent regulation of keratinocyte survival. J. Cell Sci., 110: 113-121, 1997.
56. Franke, T. F., Kaplan, D. R., and Cantley, L. C. PI3K: downstream AKT ion blocks apoptosis. Cell. 88: 435-437, 1997.
57. Turner, T., Chen, P., Goodly, L. J., and Wells, A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin. Exp. Metastasis, 14: 409-418, 1996.